Meeting Banner
Abstract #2370

Quantitative Imaging of Pharmacodynamics in a Phase 1 Clinical Study of the Vascular Disrupting Agent Crolibulin (EPC2407)

Andres M. Arias Lorza1, William L. Read2, Raoul Tibes3, Ronald L. Korn4, and Natarajan Raghunand1,5

1Department of Cancer Physiology, Moffitt Cancer Center, TAMPA, FL, United States, 2Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, United States, 3Perlmutter Cancer Center, NYU Langone Health, New York, NY, United States, 4Imaging Endpoints, LLC, Scottsdale, AZ, United States, 5Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States

Diffusion and DCE-MRI were performed at baseline and 2-3 days following Crolibulin (EPC2407) treatment in a phase 1 clinical study of this vascular disrupting agent. ADCw, Ktrans, Ve, and Vp parameter maps were computed and co-registered across scan dates. Over 10 subjects there was an average of 44% decrease in mean tumor Ktrans 2-3 days after initiation of therapy relative to baseline Ktrans values. The decrease in whole-tumor Ktrans was significantly greater in subjects who received 24 mg/m2 drug relative to those who received 13 mg/m2 Crolibulin. Voxel-wise analysis of changes in ADCw, Ktrans, Ve, and Vp will be presented.

This abstract and the presentation materials are available to members only; a login is required.

Join Here